Capitalize on the PEGylated Proteins Revenue Shift: Benchmark Amgen, Roche, Merck KGaA, Pfizer and Novo Nordisk to Secure Competitive ROI Through the Forecast Period

Company Logo Site-specific PEGylation is enabling safer, longer-acting biologics, while demand in chronic disease, targeted therapies and biosimilars creates opportunities for services and reagents. Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "PEGylated Proteins - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for PEGylated Proteins was estimated at US$2.0 Billion in 2025 and is projected to reach US$4.1 Billion by 2032, growing at a CAGR of 10.6% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.